Table 3 The top 20 prediction results of drug synergy for non-small cell lung cancer

1

Crizotinib

EMC-BAC-2

Docetaxel

0.971486

True

2

Decitabine

LC-2-ad

Ponatinib

0.927503

True

3

Fenformin

SK-LU-1

Alpelisib

0.927074

True

4

Palbociclib

LC-2-ad

Ponatinib

0.912752

True

5

Navitoclax

LC-2-ad

Everolimus

0.908936

True

6

Vorinostat

NCI-H2170

Docetaxel

0.903479

True

7

Dasatinib

PC-14

Erlotinib

0.903226

True

8

Dasatinib

HCC-827

Imatinib

0.901565

True

9

Dasatinib

NCI-H1755

Sorafenib

0.899407

True

10

Alpelisib

HCC-44

Decitabine

0.892089

True

11

Pemetrexed

LCLC-103H

Decitabine

0.891674

True

12

Navitoclax

HCC-44

Decitabine

0.89146

True

13

Vorinostat

HCC-15

Vismodegib

0.880163

True

14

Lapatinib

LC-2-ad

Etoposide

0.878746

True

15

Vorinostat

HCC-827

Sorafenib

0.874937

True

16

Navitoclax

HCC-44

Docetaxel

0.872917

True

17

Foretinib

UMC-11

Docetaxel

0.870542

True

18

Dasatinib

NCI-H2170

Docetaxel

0.868891

True

19

Fenformin

NCI-H838

Palbociclib

0.868111

True

20

Alpelisib

NCI-H2087

Sorafenib

0.861291

True